2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.
Suresh S. Ramalingam, MD, FACP, FASCO, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses ongoing trials investigating osimertinib (Tagrisso) combination approaches in non-small cell lung cancer (NSCLC).
Osimertinib is considered the standard of care in the frontline setting for patients with NSCLC, and by exploring combinations, researchers hope to reduce resistance to the agent, Ramalingam says. The phase 3 FLAURA2 trial (NCT04035486) is examining the chemotherapy with or without osimertinib in the first-line treatment of patients with EGFR-mutated NSCLC, Ramalingam explains.
Additionally, a phase 2 trial (NCT04965090) is exploring combination amivantamab (Rybrevant) and lazertinib (Leclaza) as a first-line therapy in patients with NSCLC harboring EGFR mutations, Ramalingam continues. Another potential combination for osimertinib is the antibody-drug conjugate patritumab deruxtecan (U3-1402), and there are ongoing efforts study the tandem, Ramalingam explains. The key of upcoming research will be to find optimal combinations to improve upon outcomes of osimertinib alone, Ramalingam concludes.
Funding from Daiichi Sanyko. Content Developed Independently by OncLive.